Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Guzman, Carlos A
MetadataShow full item record
AbstractDespite the broad knowledge about the pathogenicity of Streptococcus pyogenes there is still a controversy about the correlate of protection in GAS infections. We aimed in further improving the immune responses stimulated against GAS comparing different vaccine formulations including bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) and BPPCysMPEG, a derivative of the macrophage-activating lipopeptide (MALP-2), as adjuvants, respectively, to be administered with and without the universal T helper cell epitope P25 along with the optimized B cell epitope J14 of the M protein and B and T cell epitopes of SfbI. Lipopeptide based nano carrier systems (LCP) were used for efficient antigen delivery across the mucosal barrier. The stimulated immune responses were efficient in protecting mice against a respiratory challenge with a lethal dose of a heterologous S. pyogenes strain. Moreover, combination of the LCP based peptide vaccine with c-di-AMP allowed reduction of antigen dose at the same time maintaining vaccine efficacy.
CitationBivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection. 2017, 13 (8):2463-2474 Nanomedicine
AffiliationHelmholtz Centre for infection researchGmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
- Authors: Olive C, Schulze K, Sun HK, Ebensen T, Horváth A, Toth I, Guzman CA
- Issue date: 2007 Feb 26
- Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
- Authors: Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF
- Issue date: 2006 Aug 1
- Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
- Authors: Schulze K, Olive C, Ebensen T, Guzmán CA
- Issue date: 2006 Aug 28
- Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
- Authors: Abdel-Aal AB, Zaman M, Fujita Y, Batzloff MR, Good MF, Toth I
- Issue date: 2010 Nov 25
- Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
- Authors: Marasini N, Khalil ZG, Giddam AK, Ghaffar KA, Hussein WM, Capon RJ, Batzloff MR, Good MF, Skwarczynski M, Toth I
- Issue date: 2016 Nov 20